Key result
Targeted hematological therapies, particularly BTK inhibitors, are associated with increased frequency of arrhythmias such as atrial fibrillation compared to standard chemotherapy.
Why the study?
Targeted hematological therapies interfere with signaling pathways important in myocytes, leading to distinct cardiotoxic effects such as arrhythmias compared to standard chemotherapy.
Do novel targeted hematological therapies increase the risk of cardiotoxicity compared to standard chemotherapy in patients with hematological cancers?
Do novel targeted hematological therapies increase the risk of cardiotoxicity compared to standard chemotherapy in patients with hematological cancers?
This review highlights the mechanisms and clinical manifestations of cardiotoxicity, particularly arrhythmias like atrial fibrillation, associated with novel targeted hematological therapies.
Supports arrhythmia monitoring with BTK inhibitors; leaves open prospective quantification of cardiotoxicity versus chemotherapy.
Chemotherapy-related cardiac dysfunction, also known as cardiotoxicity, is a group of drug-related adverse events negatively affecting myocardial structure and functions in patients who received chemotherapy for cancer treatment. Clinical manifestations can vary from life-threatening arrythmias to chronic conditions, such as heart failure or hypertension, which dramatically reduce quality of life of cancer survivors. Standard chemotherapy exerts its toxic effect mainly by inducing oxidative stress and genomic instability, while new targeted therapies work by interfering with signaling pathways important not only in cancer cells but also in myocytes. For example, Bruton's tyrosine kinase (BTK) inhibitors interfere with class I phosphoinositide 3-kinase isoforms involved in cardiac hypertrophy, contractility, and regulation of various channel forming proteins; thus, off-target effects of BTK inhibitors are associated with increased frequency of arrhythmias, such as atrial fibrillation, compared to standard chemotherapy. In this review, we summarize current knowledge of cardiotoxic effects of targeted therapies used in hematology.
No takes yet. Share an insight, caveat, or question.
Giudice et al. (2020) conducted a review in Hematological malignancies. Targeted hematological therapies vs. Standard chemotherapy was evaluated on Cardiotoxicity. Targeted hematological therapies, particularly BTK inhibitors, are associated with increased frequency of arrhythmias such as atrial fibrillation compared to standard chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: